Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2011

Open Access 01-12-2011 | Research

Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China

Authors: Qingbin Song, Deguang Wang, Yi Lou, Changsi Li, Changqing Fang, Xiangmin He, Jianhua Li

Published in: Diagnostic Pathology | Issue 1/2011

Login to get access

Abstract

Background

To evaluate the expression and differential diagnostic significance of CK19, TG, Ki67 and galectin-3 in papillary thyroid carcinoma (PTC) (metastatic and non metastatic), follicular adenoma and nodular goiter in patients from the northeastern part of China.

Methods

441 PTC specimens and 151 other benign thyroid specimens (97 cases of nodular goiter, 54 cases of nonmalignant follicular adenoma) were collected. Immunohistochemistry for CK19, TG, Ki67 and galectin-3 was performed.

Results

CK19, TG, Ki67 and galectin-3 expression was 96.37% (425/441), 82.77% (365/441), and 40.59% (179/441), 96.82% (427/441), respectively, for the PTC group and the expression of these markers in the benign thyroid lesions group was 25.83% (39/151), 79.47% (120/151), and 37.09% (56/151), 50.99% (77/151), respectively. The expression of CK19 and galectin-3 in PTC was much higher than that in the nonmalignant group (p < 0.05). However, the expression of TG, Ki67 did not differ among these two groups (p > 0.05). The diagnostic efficiency of CK19 and galectin-3 for PTC was 96.37% (537/592) and 84.63% (501/592). CK19 and galectin-3 expression rate in PTC was higher than that in benign disease cases.

Conclusions

The diagnostic efficiency of CK19 for PTC was slightly better than galectin-3. The utilization of these markers combined with morphologic evaluation may be helpful in the differential diagnosis of papillary thyroid carcinoma in the northeastern region of China.
Appendix
Available only for authorised users
Literature
1.
Nikiforov YE: Thyroid tumors: classification and general considerations. Diagnostic Pathology and Molecular Genetics of the Thyroid. Edited by: Nikiforov YE, Biddinger PW, Thompson LDR. 2009, Lippincott Williams & Wilkins, Baltimore, MA, 94-102.
2.
DeVita VT, Hellman JS, Rosenberg SA: Cancer: principles and practice of oncology. Lippincott Williams & Wilkins. 2008, 1674-1699.
3.
Sethi K, Sarkar S, Das S, Mohanty B, Mandal M: Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol. 2010, 8: 341-352.PubMed
4.
Kato MA, Fahey TJ: Molecular markers in thyroid cancer diagnostics. Surg Clin North Am. 2009, 89: 1139-1155. 10.1016/j.suc.2009.06.012.CrossRefPubMed
5.
Nikiforov YE: Molecular analysis of thyroid tumors. Mod Pathol Suppl. 2011, 2: 34-43.CrossRef
6.
Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, Miya A: Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg. 2010, 34: 3015-21. 10.1007/s00268-010-0746-3.CrossRefPubMed
7.
Vierlinger K, Mansfeld MH, Koperek O, Nöhammer C, Kaserer K, Leisch F: Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Med Genomics. 2011, 6;4: 30-CrossRef
8.
Tan A, Etit D, Bayol U, Altinel D, Tan S: Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol. 2011, 15: 108-116. 10.1016/j.anndiagpath.2010.11.005.CrossRefPubMed
9.
Fryknäs M, Wickenberg-Bolin U, Göransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Höög A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A: Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol. 2006, 27: 211-220. 10.1159/000093056.CrossRefPubMed
10.
Magro G, Cataldo I, Amico P, Torrisi A, Vecchio GM, Parenti R, Asioli S, Recupero D, D'Agata V, Mucignat MT, Perris R: Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid. 2011, 21: 267-277. 10.1089/thy.2010.0173.CrossRefPubMed
11.
Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol. 2010, 176: 2067-2081. 10.2353/ajpath.2010.090353.PubMedCentralCrossRefPubMed
12.
Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO: Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol. 2010, 21: 80-89. 10.1007/s12022-010-9114-y.CrossRefPubMed
13.
Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, Jang HC, Park SH, Cho BY, Park SY: Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27 (kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci. 2007, 22: 621-628. 10.3346/jkms.2007.22.4.621.PubMedCentralCrossRefPubMed
14.
El Demellawy D, Nasr A, Alowami S: Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol. 2008, 3: 5-10.1186/1746-1596-3-5.PubMedCentralCrossRefPubMed
15.
Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT: Galectin-3, fibronectin-1, CITED-1, HBME-1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005, 18: 48-57. 10.1038/modpathol.3800235.CrossRefPubMed
16.
de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS: Usefulness of HBME-1, cytokeratin-19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005, 47: 391-401. 10.1111/j.1365-2559.2005.02221.x.CrossRefPubMed
17.
Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed for malin-fixed paraffin sections. J Pathol. 1992, 168: 357-363. 10.1002/path.1711680404.CrossRefPubMed
18.
Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK: Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol. 2002, 198: 157-162. 10.1002/path.1185.CrossRefPubMed
19.
Liang HS, Zhong YH, Luo ZJ, Huang Y, Lin HD, Luo M, S-Zhan Su HX, Zhou SB, Xie KQ: Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J Int Med Res. 2009, 37: 927-938.CrossRefPubMed
20.
Carpi A, Mechanick JI, Saussez S, Nicolini A: Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications. J Cell Physiol. 2010, 224: 612-619. 10.1002/jcp.22187.CrossRefPubMed
21.
Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S, Schlumberger M: Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab. 1999, 84: 3228-3234. 10.1210/jc.84.9.3228.PubMed
22.
Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET: Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002, 87: 4806-4810. 10.1210/jc.2002-020094.CrossRefPubMed
23.
Raimond J, Zimonjic DB, Mignon C, Mattei M, Popescu NC, Monsigny M, Legrand A: Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. Mamm Genome. 1997, 8: 706-707. 10.1007/s003359900548.CrossRefPubMed
24.
Türköz HK, Oksüz H, Yurdakul Z, Ozcan D: Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol. 2008, 19: 92-96. 10.1007/s12022-008-9033-3.CrossRefPubMed
25.
Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A: Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998, 58: 3015-3020.PubMed
26.
Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, Sueyoshi K, Aikou T, Sato E: Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol. 2000, 31: 428-433. 10.1053/hp.2000.6534.CrossRefPubMed
27.
Kovàcs RB, Földes J, Winkler G, Bodó M, Sápi Z: The investigation of galectin-3 in diseases of thyroid gland. Eur J Endocrinol. 2003, 149: 449-453. 10.1530/eje.0.1490449.CrossRefPubMed
28.
Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001, 357: 1644-1650. 10.1016/S0140-6736(00)04817-0.CrossRefPubMed
29.
Erkiliç S, Aydin A, Koçer NE: Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol. 2002, 13: 207-211. 10.1385/EP:13:3:207.CrossRefPubMed
30.
Fonseca E, Nesland JM, Höie J, Sobrinho-Simões M: Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins. Virchows Arch. 1997, 430: 239-245. 10.1007/BF01324808.CrossRefPubMed
31.
Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT: Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC) - like nuclear alterations expresses molecular markers of PTC. Histopathology. 2004, 45: 39-46. 10.1111/j.1365-2559.2004.01876.x.CrossRefPubMed
32.
Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G: Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology. 2006, 48: 795-800. 10.1111/j.1365-2559.2006.02428.x.CrossRefPubMed
33.
Schelfhout LJ, Van Muijen GN, Fleuren GJ: Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma. Am J Clin Pathol. 1989, 92: 654-658.PubMed
Metadata
Title
Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China
Authors
Qingbin Song
Deguang Wang
Yi Lou
Changsi Li
Changqing Fang
Xiangmin He
Jianhua Li
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2011
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-6-126

Other articles of this Issue 1/2011

Diagnostic Pathology 1/2011 Go to the issue

Case Report

Dropped head syndrome due to myogenic atrophy --- a case report of surgical treatment

Case Report

Dendritic cell tumor in a salivary gland lymph node: a rare differential diagnosis of salivary gland neoplasms

Case Report

Mesothelioma of tunica vaginalis of "uncertain malignant potential" - an evolving concept: case report and review of the literature

Database

Web-based database for the management of tissue specimens in a transregional histological research facility

Case Report

Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: A comparative clinical and histomorphological study of three cases including a new case of Carney triad

Research

Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification